Marker Therapeutics Inc (MRKR) Stock Analysis

Marker Therapeutics Inc (MRKR) is a publicly traded company in the HEALTHCARE sector. It trades at $1.42, carries a market capitalization of $25.34M. This page summarizes the public market data, fundamentals, and frequently asked questions for MRKR, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $1.42
• Market Cap: $25.34M
• EPS: $-0.55
• 52-Week High: $2.46
• 52-Week Low: $0.81

Market Sentiment

Marker Therapeutics Inc currently has a Bullish sentiment score of 0.25.

About Marker Therapeutics Inc

Marker Therapeutics Inc. is a clinical-stage immuno-oncology company dedicated to developing groundbreaking T-cell-based immunotherapies and peptide-based vaccines targeting hematologic malignancies and solid tumors. Leveraging innovative technologies to mobilize the body’s immune response against cancer, Marker Therapeutics is strategically positioned in a high-growth sector of oncology. Based in Houston, Texas, the company is focused on delivering transformative treatment solutions that aim...

GNG Research Analysis

GNG Research scores Marker Therapeutics Inc (MRKR) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for MRKR.

Frequently Asked Questions

Does MRKR pay dividends?

Marker Therapeutics Inc (MRKR) does not currently pay a regular dividend.

What is MRKR's market cap?

Marker Therapeutics Inc (MRKR) has a market capitalization of $25.34M with a current stock price of $1.42.